Literature DB >> 9506860

Reduced disorderliness of growth hormone release in biochemically inactive acromegaly after pituitary surgery.

G van den Berg1, S M Pincus, M Frölich, J D Veldhuis, F Roelfsema.   

Abstract

The episodicity of 24 h GH release was studied in 18 patients with active acromegaly, 12 patients 7-10 days after pituitary surgery, 14 patients long after operation (3-17 years), and 21 healthy gender- and age-matched control subjects, using a recently introduced scale- and model-independent regularity statistic, approximate entropy (ApEn). Blood samples were taken at 10-min intervals for 24 h, and plasma GH concentrations were measured by immunofluorometric assay (detection limit 11.5 ng/l). For this study we selected operated patients who were biochemically in remission, defined by normal circulating IGF-I and insulin-like growth factor-binding protein-3 (IGFBP-3) concentrations, normal glucose-suppressed plasma GH concentration (<0.38 microg/l), and the normalization of the paradoxical rise of GH to TRH or GnRH. In patients with active acromegaly ApEn was 1.23+/-0.04, with no overlap with the control subjects (P = 1.2 x 10[-16]), who had an ApEn of 0.40+/-0.04. ApEn in patients shortly after surgery was 0.71+/-0.09 (P < 0.001 vs controls), and long after surgery 0.56+/-0.05 (P < 0.011 vs controls). ApEn values in treated and untreated patients correlated significantly with the plasma concentration of IGF-I (r=0.531) and IGFBP-3 (r=0.598), and the log-transformed 24h GH secretion rate (r=0.749). Shortly after surgery only one-third of the patients had a normal ApEn value, whereas long after surgery about 70% of the patients had a normal ApEn value. Although ApEn eventually normalized in about 70% of the operated patients, the cause of the persistence of abnormal GH release in the remainder of the subjects is not known, and might reflect permanent hypothalamic-pituitary dysfunction or a very early recurrence of the somatotroph adenoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506860     DOI: 10.1530/eje.0.1380164

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  A novel approach to measure variability in the anterior cruciate ligament deficient knee during walking: the use of the approximate entropy in orthopaedics.

Authors:  Anastasios D Georgoulis; Constantina Moraiti; Stavros Ristanis; Nicholas Stergiou
Journal:  J Clin Monit Comput       Date:  2006-03-06       Impact factor: 2.502

Review 2.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

Review 3.  Growth hormone pulsatility in acromegaly following radiotherapy.

Authors:  S R Peacey; S M Shalet
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

4.  ACL deficiency affects stride-to-stride variability as measured using nonlinear methodology.

Authors:  Constantina Moraiti; Nicholas Stergiou; Stavros Ristanis; Anastasios D Georgoulis
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2007-09-09       Impact factor: 4.342

5.  Pituitary apoplexy in acromegaly, a long-term follow-up study in two patients.

Authors:  F Roelfsema; G van den Berg; H van Dulken; J D Veldhuis; S M Pincus
Journal:  J Endocrinol Invest       Date:  1998-05       Impact factor: 4.256

Review 6.  Human GH pulsatility: an ensemble property regulated by age and gender.

Authors:  J D Veldhuis; C Y Bowers
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

7.  Prolactin secretion in healthy adults is determined by gender, age and body mass index.

Authors:  Ferdinand Roelfsema; Hanno Pijl; Daniel M Keenan; Johannes D Veldhuis
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

Review 8.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

9.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09

10.  Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients.

Authors:  Nienke R Biermasz; Jan W A Smit; Alberto M Pereira; Marijke Frölich; Johannes A Romijn; Ferdinand Roelfsema
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.